Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 1.00 |
| ▸ | POLB | P06746 | 1/20 | 0.83 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.83 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.83 |
| ▸ | TSHR | P16473 | 1/20 | 0.83 |
| ▸ | BLM | P54132 | 1/20 | 0.83 |
| ▸ | GRIN2D | O15399 | 3/20 | 0.69 |
| ▸ | GRIN3B | O60391 | 3/20 | 0.69 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.69 |
| ▸ | GRIN2A | Q12879 | 3/20 | 0.69 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.69 |
| ▸ | GRIN2C | Q14957 | 3/20 | 0.69 |
| ▸ | GRIN3A | Q8TCU5 | 3/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29580184 | 1.00 | CYP1A2 (1.00) | CYP1A2KDM4EMEN1CYP2D6CYP2C19 | |
| SCHEMBL1998890 | 1.00 | CYP1A2 (1.00) | CYP1A2KDM4EMEN1CYP2D6CYP2C19 | |
| SCHEMBL8783900 | 0.91 | CYP1A2 (0.84) | CYP1A2KDM4EMEN1CYP2D6CYP2C19 | |
| SCHEMBL8784175 | 0.91 | CYP1A2 (0.84) | CYP1A2KDM4EMEN1CYP2D6CYP2C19 | |
| SCHEMBL8784124 | 0.91 | CYP1A2 (1.00) | CYP1A2KDM4EMEN1CYP2D6CYP2C19 | |
| SCHEMBL8784335 | 0.90 | CYP1A2 (0.82) | CYP1A2KDM4EMEN1CYP2D6CYP2C19 | |
| SCHEMBL8784512 | 0.87 | CYP1A2 (0.77) | CYP1A2KDM4EMEN1CYP2D6CYP2C19 | |
| SCHEMBL8784112 | 0.87 | CYP1A2 (0.77) | CYP1A2KDM4EMEN1CYP2D6CYP2C19 | |
| SCHEMBL8784076 | 0.87 | CYP1A2 (0.77) | CYP1A2KDM4EMEN1CYP2D6CYP2C19 | |
| SCHEMBL8783533 | 0.87 | CYP1A2 (0.77) | CYP1A2KDM4EMEN1CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4629989-A2 | TREATMENT OR PREVENTION OF DEPRESSIVE DISORDERS THROUGH COMBINATION THERAPY | Freedom Biosciences, Inc. (US) | 2025-10-15 | — | — | EP | claimed |
| US-20240350433-A1 | TREATMENT COMPOSITIONS AND METHODS | UNIV YALE (US) | 2024-10-24 | — | — | US | claimed |
| WO-2024123935-A2 | TREATMENT OR PREVENTION OF DEPRESSIVE DISORDERS THROUGH COMBINATION THERAPY | FREEDOM BIOSCIENCES, INC. (US) | 2024-06-13 | — | — | WO | claimed |
| US-20250375421-A1 | METHODS OF USING DMT | SHULMAN WILLIAM (US) | 2025-12-11 | — | — | US | disclosed |
| EP-4633638-A1 | TREATMENT OF PSYCHOLOGICAL FACTORS AFFECTING OTHER MEDICAL CONDITIONS (PFAOMC) | Luminous Mind Inc. (US) | 2025-10-22 | — | — | EP | disclosed |
| EP-4629989-A2 | TREATMENT OR PREVENTION OF DEPRESSIVE DISORDERS THROUGH COMBINATION THERAPY | Freedom Biosciences, Inc. (US) | 2025-10-15 | — | — | EP | disclosed |
| US-20250312353-A1 | DRUG REPURPOSING FOR TREATMENT OF CONGENITAL VASCULAR MALFORMATIONS | UNIVERSITY OF SOUTH CAROLINA (US) | 2025-10-09 | — | — | US | disclosed |
| US-12396981-B2 | Methods of using DMT | SHULMAN WILLIAM (US) | 2025-08-26 | — | — | US | disclosed |
| EP-4580679-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS | Biohaven Therapeutics Ltd. (VG) | 2025-07-09 | — | — | EP | disclosed |
| US-20250163130-A1 | LIGAND GATED ION CHANNELS AND METHODS OF USE | SWITCH BIO, INC. | 2025-05-22 | — | — | US | disclosed |
| US-20250152742-A1 | COMPOSITIONS AND METHODS FOR NEUROLOGICAL DISEASES | TRAMES BIO, INC. | 2025-05-15 | — | — | US | disclosed |
| US-20220348635-A1 | COMPOSITIONS AND METHODS FOR NEUROLOGICAL DISEASES | TRAMES BIO, INC. | 2022-11-03 | — | — | US | disclosed |
| US-20220244263-A1 | METHODS FOR TREATING SMALL CELL NEUROENDOCRINE AND RELATED CANCERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-08-04 | — | — | US | disclosed |
| CN-114728012-A | Ganaxolone for the treatment of status epilepticus | 马瑞纳斯制药公司 | 2022-07-08 | — | — | CN | disclosed |
| EP-3116509-B1 | A NEW CLASS OF MU-OPIOID RECEPTOR AGONISTS | UNIV COLUMBIA (US) | 2022-06-22 | — | — | EP | disclosed |
| US-20220135564-A1 | DEUTERATED MITRAGYNINE ANALOGS AS SAFER OPIOID MODULATORS IN THE MITRAGYNINE CLASS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2022-05-05 | — | — | US | disclosed |
| WO-2022074588-A1 | CARBOXYLIC DIARYLTHIAZEPINEAMINES AND USES THEREFOR | KURES, INC. (US) | 2022-04-14 | — | — | WO | disclosed |
| WO-2022074589-A1 | CARBOXYLIC DIARYLTHIAZEPINEAMINES AND USES THEREFOR | KURES, INC. (US) | 2022-04-14 | — | — | WO | disclosed |
| WO-2022074587-A1 | MU-OPIOID RECEPTOR AGONISTS AND USES THEREFOR | KURES, INC. (US) | 2022-04-14 | — | — | WO | disclosed |
| US-20220106279-A1 | CLASS OF MU-OPIOID RECEPTOR AGONISTS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2022-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12396981-B2 | Methods of using DMT | PNMT, HTR6, HTR1A | CYP1A2 1738/4885KDM4E 110/4885MEN1 1347/4885 |
| US-20220106279-A1 | CLASS OF MU-OPIOID RECEPTOR AGONISTS | OPRM1, OPRL1, OPRK1 | CYP1A2 748/4885KDM4E 2011/4885MEN1 4601/4885 |
| US-20250375421-A1 | METHODS OF USING DMT | PNMT, HTR6, HTR1A | CYP1A2 1738/4885KDM4E 110/4885MEN1 1347/4885 |
| US-20250152742-A1 | COMPOSITIONS AND METHODS FOR NEUROLOGICAL DISEASES | CHRNB2, CHRNA2, CHRNA6 | CYP1A2 4875/4885KDM4E 4711/4885MEN1 2410/4885 |
| US-20250163130-A1 | LIGAND GATED ION CHANNELS AND METHODS OF USE | CACNB2, CHRNA2, HCN3 | CYP1A2 4866/4885KDM4E 4673/4885MEN1 3711/4885 |
| US-20220135564-A1 | DEUTERATED MITRAGYNINE ANALOGS AS SAFER OPIOID MODULATORS IN THE MITRAGYNINE CLASS | OPRD1, OPRK1, OPRM1 | CYP1A2 745/4885KDM4E 910/4885MEN1 3100/4885 |
| US-20220348635-A1 | COMPOSITIONS AND METHODS FOR NEUROLOGICAL DISEASES | CHRNB2, CHRNA2, CHRNA6 | CYP1A2 4875/4885KDM4E 4711/4885MEN1 2410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.